NCT00728494View on ClinicalTrials.gov

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

CompletedOBSERVATIONAL
Enrollment

99

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Hepatitis C, ChronicHepatitis C
Interventions
BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031)

Peginterferon alfa-2b will be administered according to the product's labeling.

DRUG

Rebetol (ribavirin; SCH 18908)

Ribavirin will be administered according to the product's labeling.

BEHAVIORAL

Patient Assistance Program

"The patient assistance program includes the following:~* Training by physicians or specialized nurses.~* Informational materials based on the To beat HCV program.~* Management of specific side effects."

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00728494 - Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) | Biotech Hunter | Biotech Hunter